Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Direct biologics

Request full access

Innovative regenerative biologic products leveraging extracellular vesicles and placental-based allografts for advanced therapies

Austin, United StatesFounded 2017Biotech & Life Sciences

About Direct biologics

Direct Biologics is a pioneering biotechnology company that specializes in the development and manufacturing of regenerative biologic products. The company operates in the healthcare sector, specifically in the field of regenerative therapies. Its primary clients include hospitals and healthcare providers who are seeking innovative solutions for various health conditions, including COVID-19.

The company's flagship product is ExoFlo™, a therapeutic solution derived from bone marrow mesenchymal stem cells (MSC). These cells produce extracellular vesicles, tiny particles that carry proteins and other substances between cells. These vesicles play a crucial role in cell communication and function, including tissue repair and new blood vessel formation. ExoFlo™ leverages these properties to aid in the treatment of various health conditions.

One of the key applications of ExoFlo™ is in the treatment of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). The product is currently being used in an FDA-approved clinical trial and an FDA-approved Expanded Access Protocol for hospitals. Direct Biologics is also exploring additional clinical applications for its extracellular vesicle products through the FDA's investigational new drug (IND) application process.

Direct Biologics' business model revolves around the development, manufacturing, and sale of its regenerative biologic products. The company generates revenue through the sale of these products to healthcare providers and hospitals.

Source: Dealroom company data

At a glance

Status
Operational
Employees
56
Open positions
None listed
Dealroom signal
72.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Dec 2022 $12M $255M Undisclosed ↗
SERIES AOther financing Jun 2021 $51M $204M Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Direct biologics website traffic

Latest recorded traffic for Direct biologics is 1.3K monthly website visits, down 60.6% over the last three months. Direct biologics's team grew 7.7% over the past year.

Latest monthly visits1.3K 3-month web change-60.6% 1-year team growth+7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Nest GenomicsMaking genetic testing mainstream and integrated into patient care is difficult, Â Nest makes it easy New York City, United States Operational 17 $11M $34M
Arctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics Reykjavík, Iceland Operational
OmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists Cardiff, United Kingdom Operational
LinusBioPatient-centric precision exposome medicine, uncovering biomarkers and targets for diseases with historically limited molecular endpoints, spanning CNS, gastroenterology, renal disease, and oncology North Brunswick Township, United States Operational
ChemotargetsChemotargets is a computationally-oriented biotech company Barcelona, Spain Operational
Kantum PharmaTargeted therapies to prevent and treat damaging inflammation by the innate immune system Concord, United States Operational
United ImmunityThis company focuses on developing nanotechnology-based solutions to improve immunity and fight cancer and infectious diseases Osaka, Japan Operational
BetterOmicsAn AI cloud for omics data analysis, providing a centralized platform for reproducible validation, data traceability, and AI-powered insights, and featuring secure clinical-grade security and GxP compliance Menlo Park, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Direct biologics in the Austin ecosystem

Live from Dealroom

The Direct biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Direct biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Direct biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.